IDP-001

N/A

Report date: 2026/05/25 20:02:40

First In Class

Base Information

Drug NameIDP-001

Drug Alias NameIDP-001

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)Biologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > MMAE payload +[4]

Mechanisms of ActionAnti-Epidermal growth factor receptor erbB1Anti-CUB domain-containing protein 1Tubulin polymerisation inhibitors

TargetsEpidermal growth factor receptor erbB1TubulinCUB domain-containing protein 1

Therapy Area/IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungSquamous Cell Carcinoma of Head and Neck +[7]

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesInduPro Inc

China Registration ClassN/A

Develop Information

Active CompaniesInduPro Inc

Inactive CompaniesN/A

Active IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungSquamous Cell Carcinoma of Head and Neck +[6]

Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A